The Research of Medical Science Review
ISSN: 3007-1208 & 3007-1216 Volume 3, Issue 8, 2025

SYNTHETIC ORGANIC COMPOUNDS IN CANCER TREATMENT: MECHANISMS, CHALLENGES, AND FUTURE PROSPECTS

Areeqa Rehman[*1], Ali Rehmat[2], Ilham Ali[3], Dua Akram[4], Nouman Yousaf[5], Hafiz Muhammad Umer Ali[6]

[*1]*Department of Pathology, Islamia University of Bahawalpur, Bahawalpur, Punjab, Pakistan*
[2]*Department of Physics, NED University of Engineering Technology, Karachi, Sindh, Pakistan*
[3]*Department of Physics, Islamia College University, Peshawar, KPK, Pakistan*
[4]*Department of Nutrition and Food Technology, University of Sindh, Jamshoro, Sindh, Pakistan*
[5]*Foundation University Medical College, Islamabad Campus, Islamabad, Pakistan*
[6]*Department of Optometry and Vision Science, University of Lahore, Lahore, Punjab, Pakistan*

[*1]areeqarehman555@gmail.com

DOI: https://doi.org/10.5281/zenodo.16750162

Keywords
synthetic organic molecules, cancer therapy, molecular targets, structure–activity relationship, drug resistance, targeted therapy, small molecule inhibitors

Article History
Received on 15 April 2025
Accepted on 20 July 2025
Published on 06 August 2025

Corresponding Author: *
Areeqa Rehman

Abstract

Cancer is a predominant global cause of death, requiring the development of more targeted and effective treatment methods. Synthetic organic compounds are crucial in modern oncology because of their structural adaptability, simple large-scale synthesis, and capacity to target specific biochemical pathways associated with cancer progression. This comprehensive review examines the production, classification, and mechanisms of action of synthetic organic chemicals in cancer therapy. It underscores essential classes, including alkylating agents, antimetabolites, tyrosine kinase inhibitors, and histone deacetylase inhibitors, while emphasizing their molecular targets and cytotoxic mechanisms, such as DNA damage, enzyme inhibition, and apoptosis induction. This paper analysis the structure–activity relationships (SAR) and molecular optimization techniques that improve potency, selectivity, and pharmacokinetics. Preclinical investigations and clinical trials have illustrated the effectiveness of several synthetic agents, with prominent instances including imatinib and bortezomib attaining considerable clinical success. Notwithstanding these advancements, difficulties such drug resistance, off-target toxicity, and the intricacy of cancer microenvironment remain. Emerging trends, including combination therapies, targeted prodrug development, nanocarrier-based delivery, and artificial intelligence-driven drug design, are influencing the future of synthetic molecule applications in oncology. This study emphasizes the significance of interdisciplinary collaboration in the progression of synthetic anticancer therapies and establishes a basis for additional research to address existing limitations. This synthesis of recent findings and future provides essential insights into the significance of synthetic organic compounds in precision cancer therapy

INTRODUCTION

Cancer continues to be a significant and challenging global health issue, with almost 10 million deaths per year, and is one of the leading causes of morbidity worldwide (Bains et al., 2024; Zhang et al., 2020). Cancer pathogenesis is a complex and multifactorial process resulting from genetic mutation, epigenetic

dysregulation in gene expression, changes in signal transduction pathway activation, or evading immune response (Abdul-Hameed et al., 2024). Conventional treatment options, such as surgery, radiotherapy, and chemotherapy, have brought considerable improvement; however, they are burdened by major shortcomings such as nonspecific cytotoxicity or development of resistance and suboptimal response in the setting of metastatic disease/relapsed cancer (Abu Almaaty et al., 2021). As knowledge in cancer biology and molecular oncology continues to grow, the emphasis has shifted towards targeted and personalized treatment strategies. Among those, synthetic organic molecules have exhibited promise because of their structural diversity and ease of scale-up synthesis, as well as the ability to specifically target cancer-relevant factors at a molecular level (Kalinichenko et al., 2017).

Synthetic organic molecules are produced through chemical synthesis of carbon-based compounds and are meant to disrupt the various biochemical processes that drive cancer cell proliferation, survival, and metastasis. These molecules are unlike natural products and biologics because they can be rationally designed and manipulated through synthetic chemistry (Bains et al., 2024). Synthetic anticancer agents started with alkylating and antimetabolite drugs in the mid-20th century and are still being used today (Gao et al., 2025). Advances in drug discovery technology (medicinal chemistry, high-throughput screening, and computational modelling) have subsequently enabled the rational design of increasingly selective agents, such as tyrosine-kinase inhibitors, histone deacetylase (HDACs), proteasomes, and synthetic prodrugs. These compounds can mediate their effects through several mechanisms, including apoptosis induction, interference with DNA replication and repair, blocking angiogenesis, or modulating epigenetic expression. Owing to the structural plasticity of these scaffolds, medicinal chemists can optimize their pharmacodynamic (PD) and pharmacokinetic properties to achieve the most effective therapeutic outcomes (Nakayama et al., 2019).

The importance of synthetic organic molecules for cancer therapy is reinforced by their ability to overcome some critical limitations in classic therapies. Unlike non-selective cytotoxic agents, a large portion of synthetic compounds are aimed at targeting specific molecular abnormalities that occur only in cancer cells, or which have developed greater activity than normal (Liu et al., 2020). Moreover, synthetic molecules have more potential for oral administration and increased permeation capabilities within tissues, as well as the possibility of combining new drug delivery technologies such as nanoparticles or liposomes (Ali et al., 2022). The idea of combination therapy, including synthetic agents combined with immunotherapies and radiotherapy, or other small molecules, has also provided new directions for developing more synergistic activities as well as postponing resistance acquisition. In addition, medicinal chemistry has facilitated the generation of hybrid molecules harboring a combination of multiple pharmacophores within one agent to target several cancer pathways simultaneously (Li et al., 2023; Song et al., 2023).

With the expanding complexity of cancer therapies and a wider array of synthetic anticancer agents being discovered, there is an urgent need to update developments in their progress from discovery through approval in use and some losing ground (Singh et al., 2022). In this review, we summarize the current knowledge of synthetic organic small molecules for cancer therapy and intend to integrate relevant information on key classes of compounds involved in such therapies as well as the molecular targets against which those agents are designed, followed by their structural optimization strategy, clinical evidence at various stages with strategic implications, and prospects (Li et al., 2023). Through a critical evaluation of advances and challenges in this arena, the review endeavors to provide an integrated account of how synthetic chemistry is still innovating for precision oncology and fostering better anticancer drugs into being safer with enhanced therapeutic values (de Oliveira Filho et al., 2023).

2. Development and Classification of Synthetic Organic Anticancer Agents

Artificial organic molecules have been central in the progress of modern oncology, providing chemically defined scalable and highly modifiable reagents/compounds that can be used for therapeutic purposes. The history of synthetic anticancer agents has reflected advances in cancer chemotherapy over

decades, with breaches being made first by serendipity, for example, nitrogen mustards from the middle of the 20th century to a more rational structure-guided design approach that is observed today (Stuart et al., 2023). These molecules are synthesized rationally, usually from heterocyclic core and aromatic substitutions, as well as functionalized side groups, to improve biological specificity and stability as shown in Figure 1. In contrast to biologics or natural product-derived agents, synthetic small molecules have the advantage of structural versatility and tend to exhibit favorable pharmacokinetic properties such as oral bioavailability, metabolic stability, and membrane permeability (Goracci et al., 2020). Medicinal chemists have leveraged this chemical tractability to design drugs that specifically block oncogenic pathways or essential cellular functions that are restricted to tumor cells. The development of high-throughput screening techniques and combinatorial chemistry has additionally hastened the discovery of lead compounds, and computer-assisted drug design has facilitated cost-effective SAR–activity relationship (SAR) analysis with subsequent refining of molecular templates to afford drugs possessing desirable therapeutic indices (Szczepańska et al., 2020).

Synthetic organic anticancer drugs are generally categorized according to their mechanism of action and molecular target specificity. First-generation drug classes include alkylating agents, such as cyclophosphamide and busulfan; these drugs create covalent adducts on DNA, leading to strand crosslinking, ultimately culminating in apoptosis. Antimetabolites, including methotrexate and 5-fluorouracil, are analogues of endogenous purines or pyrimidines which inhibit the synthesis of DNA, and in some instances, RNA (Horgan et al., 2025). Topoisomerase inhibitors, such as etoposide and irinotecan, prevent enzymes from relaxing supercoiled DNA during replication, causing damage to that molecule sequence and leading to cell death. More recently, targeted therapies, such as tyrosine kinase inhibitor (TKIs) imatinib in BCR-ABL-driven chronic myeloid leukemia and erlotinib in EGFR-mutant non-small cell lung cancer, have transformed the landscape of precision medicine. These substances target certain proteins that mediate oncogenic signaling, thereby providing increased selectivity and reduced systemic toxicity (Horgan et al., 2025). In addition, classes including histone deacetylase (HDAC) inhibitors (vorinostat) and proteasome inhibitors (bortezomib) have been developed that target epigenetic and protein degradation machinery, respectively (Brown et al., 2022). Synthetic heterocycles, including bioactive natural product analogues that have been chemically optimized for enhanced efficacy, are still being investigated. In the last few years, hybrids of different pharmacophores (kinase-inhibitor/DNA intercalator) have been prepared to circumvent resistance and increase multitarget engagement. Together, these classes emphasize the variety of chemical tactics leveraged in synthetic oncology—this group reflects a push to produce agents that are cytotoxic but also mechanistically selective and tailored against tumor heterogeneity (Stuart et al., 2023).



Figure 1: Flowchart illustrates the development pipeline of synthetic organic anticancer agents from lead identification to clinical application in oncology.

3. Mechanisms of Action and Molecular Targets

Chemotherapeutic drugs based on synthetic organic molecules work by blocking specific molecular pathways essential for cell proliferation, survival, and genome integrity as shown in Figure 2. A major mode of action is induction of DNA damage by direct alkylation or inhibition of enzymes that repair the DNA. Covalent adducts of DNA bases formed by alkylating agents, including cyclophosphamide, cause cross-linking and strand breaks, resulting in apoptosis (Dashtaki & Ghasemi, 2023). Other agents like platinum-based complexes (for example, cisplatin--though strictly speaking an organometal– are commonly co-synthesized with organic analogues) nonetheless operate by similar DNA-binding mechanisms. Topoisomerase inhibitors such as topotecan and etoposide inhibit the re-ligation stage of the topoisomerase-mediated DNA cleavage cycle, leading to sustained double-strand breaks in DNA (Harry & Ormiston, 2021). These lesions activate DNA damage response pathways and, if unrepairable, cause programmed cell death. Antimetabolites, such as 5-fluorouracil (5-FU) and gemcitabine, inhibit de novo nucleotide synthesis or are incorporated into nucleic acids to provide premature chain termination in DNA replication and transcription (Yao et al., 2023).

Another important category of synthetic agents inhibits signal transduction pathways, which are hyperactivated in cancer cells. Tyrosine kinase inhibitors (TKIs) are the best examples of this approach; they compete for binding to these ATP atpases, which belong to particular kinases involved in oncogenic signaling. For example, imatinib inhibits the BCR-ABL oncoprotein in chronic myeloid leukemia (CML) by specifically blocking downstream proliferative signals (Mukherjee & Patra, 2016). Gefitinib and erlotinib also block the epidermal

growth factor receptor (EGFR), which is frequently mutated or overexpressed in non-small-cell lung carcinoma. These compounds inhibit receptor phosphorylation and downstream signaling pathways, such as PI3K/AKT and RAS/MAPK (Lopes-Coelho et al., 2021). Outside the kinase family, drugs are synthetic inhibitors of epigenetic enzymes, including histone deacetylases (HDACs). HDACis, such as vorinostat, cause hyperacetylation of histone proteins with concomitant re-expression of TSGs and apoptosis. A second key mechanism is anti-angiogenesis, in which molecules such as thalidomide analogues and receptor tyrosine kinase inhibitors (VEGFRs) affect the formation of new blood vessels critical for tumor growth and spread. In addition, some synthetic molecules interfere with degradation by proteasomes, such as bortezomib (an inhibitor of 26S protease) which causes an increase in the levels of pro-apoptotic proteins and arrests the cell cycle (Bastani et al., 2021).

Crucially, synthetic compounds can be targeted at several molecular targets simultaneously, either by virtue of their pleiotropic nature or through rational combination modules. For instance, dual PI3K/mTOR inhibitors have been developed to circumvent feedback activation and redundancy in signaling pathways. Indeed, prodrug strategies are under development where an inert compound is activated specifically in the tumor micro therapy environment by pH or enzymatic conditions, resulting in less off-target toxicity (Li et al., 2019). By applying synthetic chemistry, the binding affinity and selectivity can be optimized. Furthermore, the use of structure-guided drug design and computational modelling has allowed the development of inhibitors that exhibit sub-nanomolar potency against established targets. On occasion, synthetic agents may also act as immune modulators—by activating T cells or promoting antigen presentation—and thereby providing an intersection between 'conventional' cytotoxic therapy and immuno-oncology (Su et al., 2024). Overall, the mechanistic heterogeneity of synthetic organic molecules reflects their versatility and intricacy in engaging cancer-selective vulnerabilities with current work on developing resistance-busting and high-impact clinical treatments (Méndez-Valdés et al., 2023).

Figure 2: *Mechanistic classification of synthetic organic anticancer molecules based on their molecular targets and modes of action, including DNA interaction, enzyme inhibition, signal modulation, and tumor-specific activation.*

4. Structure–Activity Relationship (SAR) and Molecular Optimization

Structure–activity relationship (SAR) forms the core of synthetic organic anticancer agents. SAR involves systematic exploration of how changes in a molecule's structure and physical properties impact on its biological activity for the purpose of discovering optimized chemical attributes essential for therapeutic benefit (Latham et al., 2024). SAR analyses are used by medicinal chemists to derive pharmacophores with minimum structural requirements for receptor binding and activity from lead compounds (Gagic et al., 2020). Researchers can test how these changes affect potency, selectivity, and solubility by systematically changing substituents on the central scaffold, for example, rings of aromatic carbon atoms (with or without electron-donating or electron-withdrawing groups), introduction of organic heteroatoms, and alterations in their metabolism stability/toxicity profile (Hu et al., 2021). For instance, in the design of kinase inhibitors, modifications to the hinge binding region may increase ATP-binding pocket affinity and selectivity over homologous kinases. In the same context, it is known that fluorination of aromatic rings in anticancer agents such as fluorouracil increases metabolic stability and membrane penetration. The iterative process of chemical modifications is driven by in vitro screening and docking studies, as well as increasing AI methods for predicting activity from molecular descriptors (Bertrand et al., 2022).

In addition to improving potency, molecular optimization also confronts issues that involve multi-drug resistance (MDR), poor bioavailability, and off-target toxicity. One popular approach is conjugating prodrug moieties—inactive groups that are enzymatically or chemically cleaved in the local tumor environment, resulting in an active drug—to improve selectivity of tumors and minimize toxicity (Sharma et al., 2024). However, as an alternative approach to single-molecule testing, one can design hybrid molecules containing at least two molecules with different modes of action within the same molecule (DNA intercalators attached to kinase inhibitors, HDAC, and alkylating groups). Such multi-pathway active agents are likely to be less vulnerable to resistance development through the simultaneous interaction of different pathways, and accordingly more potent in killing the pathogens (Li et al., 2020). Lipophilic or ionizable groups are commonly introduced to optimize membrane permeability, while PEGylation and the addition of biodegradable carriers can enhance solubility and overall circulation time (Farran et al., 2017). Structure-based drug design and molecular modelling – Knowledge of the crystal structures of target proteins can be used to design compounds with perfect fit as well as minimal off-target binding (Bhalla & Estrela, 2017). Quantitative SAR (QSAR) and molecular docking computations are illustrative supplementations to provide predictive estimation of binding affinity, which may allow us to prioritize synthetic candidates for biological testing. In the end, SAR and optimization efforts are required to translate chemical envelopes into clinically viable drugs that engage their biological targets effectively while possessing acceptable pharmacokinetic/ADME properties as well as safety profiles (Balupuri et al., 2016).

5. Preclinical and Clinical Evidence

The journey from synthetic compounds to clinically approved anticancer drugs is heavily dependent on strong preclinical validation. At the outset, in vitro tests are used to evaluate cytotoxicity against a panel of human cancer cell lines (HeLa, MCF-7, A549), establishing initial dose-response relationships and IC_{50} values with indication on the mechanism of action leading to cell death (apoptosis/necrosis/autophagy). The reporting also typically involves mechanistic studies such as western blot analysis for protein expression changes, flow cytometry assays of cell cycle, and fluorescence microscopy using apoptosis markers (Shimizu et al., 2025). Subsequently, in vivo testing using xenograft models of genetically engineered mice or patient-derived tumors is conventional for researchers to determine how effective a drug can be at the whole-organism level. Measurements are made in terms of tumor regression, survival, and systemic toxicity. For example, drugs that specifically target tyrosine kinases not found in normal adult stem cells have shown selective tumor regression (> imatinib) of BCR-ABl-induced leukemia mouse models before moving into clinical trials (Naik et al., 2023). Likewise, HDAC inhibitors and chemical proteasome inhibitor agents have been extensively tested in preclinical studies for

properties such as bioavailability, metabolism, and toxicity before their use in humans. PK/PD profiling is also critical as it provides information on dosing and formulation. Together, preclinical studies provide proof-of-concept validation for candidate markers and a rationale for proceeding with human trials (Di Federico et al., 2021).

The proof of principle for synthetic organic compounds in oncology is also illustrated by their performance as drugs tested in human trials. For example, imatinib (Gleevec) was quickly translated into clinical trials for the treatment of chronic myeloid leukemia (CML) based on its outstanding specificity and effectiveness in producing long-term remissions with minimal off-target toxicity. Likewise, erlotinib and gefitinib showed a substantial survival benefit in EGFR-mutated NSCLC patients (Tian et al., 2025). The synthetic HDAC inhibitor (vorinostat) and proteasome inhibitors (e.g. bortezomib), when used in a clinical trial of cutaneous T cell lymphoma or multiple myelomas, respectively, showed composite factor increase rates for disease progression-free survival. The program is developed in an organized, staged pattern: as first-in-human trials define MTD/DLT and PK profiles (Phase I) or the efficacy of new agents for a specific cancer (Phase II), comparison studies to standard therapy are performed with a larger number of patients/cohorts. Throughout these phases, molecular biomarkers are frequently employed to stratify patients within a certain subpopulation group to provide accurate treatment (Metibemu et al., 2019). However, despite impressive preclinical performance, some synthetic molecules have not been tested in clinical trials, as they either lack efficacy or lead to off-target effects and unexpected toxicities. This finding supports the need for more advanced preclinical models that can recapitulate tumor heterogeneity and the human microenvironment. The substantial influx of novel synthetic compounds into clinical oncology following successful regulatory approval highlights their essential role in the advancement of cancer therapeutics (Ono et al., 2021).

6. Challenges and Emerging Trends

Although much has been accomplished regarding the discovery and clinical application of synthetic organic anticancer agents, certain formidable barriers continue to hinder their optimal therapeutic effectiveness. One of the major issues is drug resistance (Figure 3), which can be intrinsic (the tumor cells already had this property prior to treatment) or acquired during therapy. Resistance mechanisms to chemotherapy generally involve the activation of drug efflux using ATP-binding cassette (ABC) transporters, such as P-glycoprotein; mutations in drug targets, including the T790M mutation for EGFR inhibitors; alternative signaling pathways; and upregulation of DNA repair machinery (Zhao et al., 2021). Moreover, off-target toxicity is still a major issue for agents that are not sufficiently selective. For example, alkylating agents and some kinase inhibitors exhibit toxicity against healthy rapidly dividing cells, causing myelosuppression, gastrointestinal toxicity (GIT), and cardiotoxicity (Poojan et al., 2020). The tumor microenvironment (TME) also has profound impacts on treatment efficacy; hypoxia, abnormal vasculature, and the presence of immunosuppressive cell populations inside the TME can restrict drug delivery while promoting resistance (Beklen et al., 2020). A further issue is that preclinical models do not predict well; many molecules which perform adequately in vitro or as animal model-based systems fail to translate across due to differential metabolism, immune response, and tumor heterogeneity. Additionally, the synthesis cost and scalability can be prohibitive (especially for complex or multi-chiral molecules) to low-resource settings (Xin et al., 2021).

To overcome these challenges, multiple novel directions are being identified that will influence synthetic anticancer drug discovery in the future. One promising approach is a rational combination treatment strategy, in which synthetic small molecules are combined with immunotherapies (checkpoint inhibitors), targeted biologics, or radiation to improve therapeutic efficacy and delay resistance (Wang et al., 2017). Nanotechnology has provided us with additional novel opportunities to target synthetic drugs more selectively into tumor tissues, through liposomes, dendrimers, or polymeric nanoparticles with improved solubility and circulation time, yet enabling better penetration inside a solid cancer. Yet another promising area is the use of AI/ML for drug discovery which can provide predictions on binding affinities, optimize synthetic pathways, and unveil novel bioactive scaffolds with outstanding prediction

accuracy (Mansoori et al., 2017). In addition, Proteolysis-Targeting Chimeras (PROTACs) and other targeted protein degradation agents comprise a new class of synthetic molecules that act beyond inhibition by inducing full target removal at the level of proteostasis. Tumor-targeted prodrugs and environment-responsive linkers that enable tumor-specific drug activation in the hypoxia/acidosis/enzyme locality of tumors have also attracted increasing interest (Yi & Wagner, 2022). Lastly, the precision oncology era is being supported by personalized synthetic chemicals designed around one's genetics or epigenetics status with help from genomics, transcriptomics, and molecular diagnostic advances. Collectively, these advancements have signified a transformative shift in the development of more intelligent and selective cancer therapeutics. They also contribute to the modification of the chemical space, facilitating the synthesis of molecules, and advancing the field of synthetic organic chemistry (Zhao et al., 2019).



Figure 3: *Flowchart depicting key challenges in synthetic anticancer therapy and emerging innovative solutions, enabling technologies, and future directions in drug design and personalized oncology.*

7. Conclusion

Synthetic organic molecules play an irreplaceable role in the battle against cancer, providing abundant chemical scaffolds with clear mechanisms and the potential for scalable drug development. These drugs have revolutionized oncology by allowing molecularly targeted abrogation of tumor-specific pathways, ranging from alkylating agents and antimetabolites to more recent kinase inhibitors and HDAC modulators. Their development is driven by a robust database of structure–activity relationship (SAR) studies and advancements in molecular optimization approaches to improve potency, selectivity, and pharmacokinetic properties. Preclinical studies of many synthetic agents have been carried out in cellular and animal models, with some successful clinical trials leading to standard-of-care therapies. Despite these improvements, issues including drug resistance, off-target toxicity, and inefficient drug delivery still hinder therapeutic response. The tumor microenvironment and genetic heterogeneity also make it more difficult to obtain treatment effectiveness; thus, the development of better molecular designs as well as prediction models is a major challenge. New emerging technologies, such as nanocarrier systems, rational drug combination construction approaches, AI-guided drug discovery, and protein degradation techniques, are providing novel strategies to bypass these limitations. Additionally, personalized medicine and combining

synthetic molecules with genomic and immunological knowledge will guide the future of cancer therapeutics. As the field progresses, continued interaction of synthetic chemists, pharmacologists, and oncologists must be encouraged along with that of computational biologists to facilitate more rapid translation from these compounds into clinically effective but also safe and affordable treatments. This Review emphasizes the importance of synthetic organic chemistry in existing and emerging cancer therapeutic approaches, arguing for further innovation in molecular design versus disease strategy to address the expanding spectrum of oncological burdens.

REFRENCES

Abdul-Hameed, Y., Alwan, S. M., & Dawood, A. H. (2024). Molecular docking, synthesis and preliminary evaluation of hybrid molecules of benzothiazole cross-linked with hydroxamic acid by certain linkers as HDAC inhibitors. *F1000Research*, *13*, 1212.

Abu Almaaty, A. H., Elgrahy, N. A., Fayad, E., Abu Ali, O. A., Mahdy, A. R., Barakat, L. A., & El Behery, M. (2021). Design, synthesis and anticancer evaluation of substituted cinnamic acid bearing 2-quinolone hybrid derivatives. *Molecules*, *26*(16), 4724.

Ali, A. A., Abuwatfa, W. H., Al-Sayah, M. H., & Husseini, G. A. (2022). Gold-nanoparticle hybrid nanostructures for multimodal cancer therapy. *Nanomaterials*, *12*(20), 3706.

Bains, O., Kumar, A., Kamal, R., Kour, R., Kaur, S., Kaur, S., Jangra, R., Sharma, P., & Kumar, R. (2024). Synthesis, Anticancer Evaluation, in-silico ADMET and Molecular Docking Studies for Tailored Pyrazolo-Benzothiazole Hybrids. *Asian Journal of Organic Chemistry*, *13*(11), e202400187.

Balupuri, A., Balasubramanian, P. K., & Cho, S. J. (2016). Comparative molecular field analysis of pyrrolopyrimidines as LRRK2 kinase inhibitors. *Journal of Integrative Natural Science*, *9*(1), 1-9.

Bastani, S., Akbarzadeh, M., Rastgar Rezaei, Y., Farzane, A., Nouri, M., Mollapour Sisakht, M., Fattahi, A., Akbarzadeh, M., & Reiter, R. J. (2021). Melatonin as a therapeutic agent for the inhibition of hypoxia-induced tumor progression: a description of possible mechanisms involved. *International Journal of Molecular Sciences*, *22*(19), 10874.

Beklen, H., Gulfidan, G., Arga, K. Y., Mardinoglu, A., & Turanli, B. (2020). Drug repositioning for P-glycoprotein mediated co-expression networks in colorectal cancer. *Frontiers in Oncology*, *10*, 1273.

Bertrand, J., Dostálová, H., Kryštof, V., Jorda, R., Delgado, T., Castro-Alvarez, A., Mella, J., Cabezas, D., Faúndez, M., & Espinosa-Bustos, C. (2022). Design, synthesis, in silico studies and inhibitory activity towards Bcr-Abl, BTK and FLT3-ITD of new 2, 6, 9-trisubstituted purine derivatives as potential agents for the treatment of Leukaemia. *Pharmaceutics*, *14*(6), 1294.

Bhalla, N., & Estrela, P. (2017). Biosensors for screening kinase inhibitors. *Current Topics in Medicinal Chemistry*, *17*(22), 2470-2481.

Brown, L. J., Achinger-Kawecka, J., Portman, N., Clark, S., Stirzaker, C., & Lim, E. (2022). Epigenetic therapies and biomarkers in breast cancer. *Cancers*, *14*(3), 474.

Dashtaki, M. E., & Ghasemi, S. (2023). Anti-angiogenic drug resistance: Roles and targeting of non-coding RNAs (microRNAs and long non-coding RNAs). *Current Molecular Pharmacology*, *16*(8), 855-869.

de Oliveira Filho, R. S., de Oliveira, D. A., Nisimoto, M. M., & Marti, L. C. (2023). A review of advanced cutaneous melanoma therapies and their mechanisms, from immunotherapies to lysine histone methyl transferase inhibitors. *Cancers*, *15*(24), 5751.

Di Federico, A., Tateo, V., Parisi, C., Formica, F., Carloni, R., Frega, G., Rizzo, A., Ricci, D., Di Marco, M., & Palloni, A. (2021). Hacking pancreatic cancer: present and future of personalized medicine. *Pharmaceuticals*, *14*(7), 677.

Farran, B., Müller, S., & Montenegro, R. C. (2017). Gastric cancer management: kinases as a target therapy. *Clinical and Experimental Pharmacology and Physiology*, *44*(6), 613-622.

Gagic, Z., Ruzic, D., Djokovic, N., Djikic, T., & Nikolic, K. (2020). In silico methods for design of kinase inhibitors as anticancer drugs. *Frontiers in chemistry*, *7*, 873.

Gao, Y., Liu, J., Wu, M., Zhang, Y., Wang, M., Lyu, Q., Zhang, W., Zhou, Y., Cheuk, Y. C., & Wang, X. (2025). Photosensitive Hybrid γδ-T Exosomes for Targeted Cancer Photoimmunotherapy. *ACS nano*, *19*(4), 4251-4268.

Goracci, M., Pignochino, Y., & Marchiò, S. (2020). Phage display-based nanotechnology applications in cancer immunotherapy. *Molecules*, *25*(4), 843.

Harry, J. A., & Ormiston, M. L. (2021). Novel pathways for targeting tumor angiogenesis in metastatic breast cancer. *Frontiers in Oncology*, *11*, 772305.

Horgan, D., Hofman, P., Schneider, D., Malapelle, U., & Subbiah, V. (2025). From dominance to decline: Can we reverse the trend in small molecule and TKI cancer therapies? *Pathologica*, *117*(3), 199.

Hu, L., Yang, Y., Zheng, S., Xu, J., Ran, T., & Chen, H. (2021). Kinase inhibitor scaffold hopping with deep learning approaches. *Journal of Chemical Information and Modeling*, *61*(10), 4900-4912.

Kalinichenko, S., Shepelev, M., Vikhreva, P., & Korobko, I. (2017). A novel hybrid promoter ARE-hTERT for cancer gene therapy. *Acta Naturae (англоязычная версия)*, *9*(4 (34)), 66-73.

Latham, B. D., Geffert, R. M., & Jackson, K. D. (2024). Kinase inhibitors FDA approved 2018–2023: drug targets, metabolic pathways, and drug-induced toxicities. *Drug Metabolism and Disposition*, *52*(6), 479-492.

Li, J., Song, W., & Li, F. (2023). Polymeric DNA hydrogels and their applications in drug delivery for cancer therapy. *Gels*, *9*(3), 239.

Li, S., Xu, H.-X., Wu, C.-T., Wang, W.-Q., Jin, W., Gao, H.-L., Li, H., Zhang, S.-R., Xu, J.-Z., & Qi, Z.-H. (2019). Angiogenesis in pancreatic cancer: current research status and clinical implications. *Angiogenesis*, *22*(1), 15-36.

Li, X., Xu, Y., Yao, H., & Lin, K. (2020). Chemical space exploration based on recurrent neural networks: applications in discovering kinase inhibitors. *Journal of cheminformatics*, *12*(1), 42.

Liu, F., Wang, X.-d., & Du, S.-y. (2020). Production of gold/silver doped carbon nanocomposites for effective photothermal therapy of colon cancer. *Scientific Reports*, *10*(1), 7618.

Lopes-Coelho, F., Martins, F., Pereira, S. A., & Serpa, J. (2021). Anti-angiogenic therapy: current challenges and future perspectives. *International Journal of Molecular Sciences*, *22*(7), 3765.

Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017). The different mechanisms of cancer drug resistance: a brief review. *Advanced pharmaceutical bulletin*, *7*(3), 339.

Méndez-Valdés, G., Gómez-Hevia, F., Lillo-Moya, J., González-Fernández, T., Abelli, J., Cereceda-Cornejo, A., Bragato, M. C., Saso, L., & Rodrigo, R. (2023). Endostatin and cancer therapy: a novel potential alternative to anti-VEGF monoclonal antibodies. *Biomedicines*, *11*(3), 718.

Metibemu, D. S., Akinloye, O. A., Akamo, A. J., Ojo, D. A., Okeowo, O. T., & Omotuyi, I. O. (2019). Exploring receptor tyrosine kinases-inhibitors in Cancer treatments. *Egyptian Journal of Medical Human Genetics*, *20*(1), 1-16.

Mukherjee, S., & Patra, C. R. (2016). Therapeutic application of anti-angiogenic nanomaterials in cancers. *Nanoscale*, *8*(25), 12444-12470.

Naik, R., Avula, S., Palleti, S. K., Gummadi, J., Ramachandran, R., Chandramohan, D., Dhillon, G., Gill, A. S., Paiwal, K., & Shaik, B. (2023). From emergence to endemicity: a comprehensive review of COVID-19. *Cureus*, *15*(10).

Nakayama, M., Lim, W. Q., Kajiyama, S., Kumamoto, A., Ikuhara, Y., Kato, T., & Zhao, Y. (2019). Liquid-crystalline hydroxyapatite/polymer nanorod hybrids: potential bioplatform for photodynamic therapy and cellular scaffolds. *ACS Applied Materials & Interfaces*, *11*(19), 17759-17765.

Ono, A., Murakami, H., Seto, T., Shimizu, T., Watanabe, S., Takeshita, S., Takeda, K., Toyoshima, J., Nagase, I., & Bahceci, E. (2021). Safety and antitumor activity of repeated ASP3026 administration in Japanese patients with solid tumors: a phase I study. *Drugs in R&D*, *21*(1), 65-78.

Poojan, S., Bae, S.-H., Min, J.-W., Lee, E. Y., Song, Y., Kim, H. Y., Sim, H. W., Kang, E.-K., Kim, Y.-H., & Lee, H.-O. (2020). Cancer cells undergoing epigenetic transition show short-term resistance and are transformed into cells with medium-term resistance by drug treatment. *Experimental & Molecular Medicine*, *52*(7), 1102-1115.

Sharma, K., Sharma, A., Sanduja, M., & Kumar, A. (2024). Unravelling the Design and Mechanism: Potential of Substituted Quinolines as PASTA subunit 4 Inhibitors for Antimicrobial Activity. *ChemistrySelect*, *9*(16), e202400194.

Shimizu, N., Kanemitsu, S., Umemura, R., Yashiro, T., Kawabata, R., Nishimura, K., Kawasaki, S., Morita, K., Aoi, T., & Maruyama, T. (2025). Mechanistic Insights into the Apoptosis of Cancer Cells Induced by a Kinase-Responsive Peptide Amphiphile. *Chemistry–A European Journal*, *31*(13), e202403658.

Singh, A. K., Kumar, A., Singh, H., Sonawane, P., Paliwal, H., Thareja, S., Pathak, P., Grishina, M., Jaremko, M., & Emwas, A.-H. (2022). Concept of hybrid drugs and recent advancements in anticancer hybrids. *Pharmaceuticals*, *15*(9), 1071.

Song, X., Wu, Y., Qu, X., & Jiang, B. (2023). Applications of macrocyclic molecules in cancer therapy: Target cancer development or overcome drug resistance. *MedComm–Oncology*, *2*(3), e50.

Stuart, D. D., Guzman-Perez, A., Brooijmans, N., Jackson, E. L., Kryukov, G. V., Friedman, A. A., & Hoos, A. (2023). Precision oncology comes of age: designing best-in-class small molecules by integrating two decades of advances in chemistry, target biology, and data science. *Cancer Discovery*, *13*(10), 2131-2149.

Su, Z., Li, W., Lei, Z., Hu, L., Wang, S., & Guo, L. (2024). Regulation of angiogenesis by non-coding RNAs in cancer. *Biomolecules*, *14*(1), 60.

Szczepańska, J., Błasiak, J., Chojnacki, J., Pawłowska, E., & Chojnacki, C. (2020). Nutrition in Cancer Therapy in the Elderly-An Epigenetic Connection? *Nutrients*, *12*(11).

Tian, Z., Cen, L., Wei, F., Dong, J., Huang, Y., Han, Y., Wang, Z., Deng, J., & Jiang, Y. (2025). EGFR mutations in non-small cell lung cancer: Classification, characteristics and resistance to third-generation EGFR-tyrosine kinase inhibitors. *Oncology Letters*, *30*(2), 375.

Wang, S., Wang, A., Shao, M., Lin, L., Li, P., & Wang, Y. (2017). Schisandrin B reverses doxorubicin resistance through inhibiting P-glycoprotein and promoting proteasome-mediated degradation of survivin. *Scientific Reports*, *7*(1), 8419.

Xin, C., Huang, F., Wang, J., Li, J., & Chen, Q. (2021). Roles of circRNAs in cancer chemoresistance. *Oncology Reports*, *46*(4), 225.

Yao, C., Wu, S., Kong, J., Sun, Y., Bai, Y., Zhu, R., Li, Z., Sun, W., & Zheng, L. (2023). Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies. *Cancer biology & medicine*, *20*(1), 25-43.

Yi, T., & Wagner, G. (2022). Cytocapsular tubes and networks function as physical superdefence freeway systems conducting conventional cancer drug pan-resistant tumor metastasis. *BioRxiv*, 2022.2001. 2005.475158.

Zhang, C., Fortin, P. Y., Barnoin, G., Qin, X., Wang, X., Fernandez Alvarez, A., Bijani, C., Maddelein, M. L., Hemmert, C., & Cuvillier, O. (2020). An Artemisinin-Derivative–(NHC) Gold (I) Hybrid with Enhanced Cytotoxicity through Inhibition of NRF2 Transcriptional Activity. *Angewandte Chemie International Edition*, *59*(29), 12062-12068.

Zhao, W., Shan, B., He, D., Cheng, Y., Li, B., Zhang, C., & Duan, C. (2019). Recent progress in characterizing long noncoding RNAs in cancer drug resistance. *Journal of Cancer*, *10*(26), 6693.

Zhao, Y., Chen, Y., Wang, J., & Liu, L. (2021). Effects of ATP-binding cassette transporter G2 in extracellular vesicles on drug resistance of laryngeal cancer cells in in vivo and in vitro. *Oncology Letters*, *21*(5), 364.